EP Patent

EP3204497A1 — Therapeutic inhibition of lactate dehydrogenase and agents therefor

Assigned to Dicerna Pharmaceuticals Inc · Expires 2017-08-16 · 9y expired

What this patent protects

This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g ., Dicer substrate siRNA (DsiRNA) agents.

USPTO Abstract

This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g ., Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

Patent Metadata

Patent number
EP3204497A1
Jurisdiction
EP
Classification
—
Expires
2017-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Dicerna Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.